Veterinary Vaccines Market: Growth, Size, Share, and Trends

Report Code PH 3475
Published in Jan, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Veterinary Vaccines Market by Type (Porcine, Poultry, Livestock, Companion Animals), Technology (Live Attenuated, Inactivated, Toxoid), Route of Administration (Intramuscular, Subcutaneous, Oral), End user (Hospitals, Clinics) - Global Forecast to 2029

Overview

The global veterinary vaccines market, valued at US$8.93 billion in 2023, is forecasted to grow at a robust CAGR of 6.1%, reaching US$9.39 billion in 2024 and an impressive US$13.33 billion by 2029. Growing awareness of animal health, along with the rising pet population and ownership, is driving the adoption of veterinary vaccines. Government efforts to improve animal health and the increasing popularity of pet insurance are also contributing to this trend. In markets like North America and Europe, more pet owners are buying insurance due to higher spending on pet care. Additionally, the focus on developing new and advanced vaccines, along with their growing use in emerging economies, is expected to fuel market growth.

Veterinary Vaccines Market

Attractive Opportunities in the Veterinary Vaccines Market

Asia Pacific

Market growth in the Asia Pacific can be attributed to the growing population of companion animals, increased focus on improving animal health and productivity

Initiatives by various government agencies and animal associations, rising demand for animal-derived food products are key factors driving the market growth.

Technological advancements and untapped emerging markets are factors expected to provide lucrative opportunities for market players.

The European veterinary vaccines market is expected to be worth USD 3.79 billion by 2029, growing at CAGR of 5.5% during the forecast period.

Shortage of veterinarians and lack of animal healthcare awareness in emerging countries are expected to pose a challenge to the growth of this market.

Global Veterinary Vaccines Market Dynamics

DRIVER: Rise in companion animal population and pet ownership

Over the years, companion animals such as dogs and cats have been transformed and raised remarkably. Most homes in the Western, especially North America, now have companion animals. Also, in developing countries such as India and China, the population of companion animals has steadily increased in recent years. Growth in pet population is expected to drive demand for pet care products and services, which in turn will support the growth of dependent industries like veterinary vaccines. As per the National Pet Owners Survey (2023-2024) by the American Pet Products Association, approximately 86.9 million U.S. families (or 66%) own some form of a pet. The American Veterinary Medical Association gave such statistics as this steadily increasing pet-owning household, which is going higher and higher, from 31.3 million in 1996 to 59.8 million in 2024.

According to the Global State of Pet Care 2022, pet ownership is soaring worldwide, with over a billion pets owned around the globe and more than half the world's inhabitants estimated to have a pet. The U.S., Brazil, the EU, and China alone account for over half a billion dogs and cats. This ever-increasing global trend in pet ownership, including emerging economies, is a phenomenon linked to changes in social norms and increased realization of the resultant benefits of keeping pets to human well-being. Such trends are expected to fuel the development of the animal health industry and thus cause ripples causing the growth of dependent markets such as the veterinary vaccines market.

RESTRAINT: High cost associated with vaccines

The development and manufacturing of veterinary vaccines, especially regarding complicated diseases, require a very heavy investment for research, development, and manufacture. These costs often create a high barrier in the development of vaccines for rare diseases or those emerging. High production costs may also restrict the affordability and availability of vaccines, most particularly in poorer regions or small farmers and pet owners. The result is often an increased unavailability of essential vaccines that can make disease prevention efforts ineffective in such regions. Overall, R&D costs differ significantly for vaccine development as it is estimated that the total cost could be between USD 200 million to USD 500 million. This includes the entire process from the initial research to market introduction. Also Manufacturing facilities cost a large amount of investment. Setting up compliant facilities for manufacture costs between USD 50 million and USD 500 million' per antigen. Facilities designed to cater to multiple vaccines may cost up to USD 700 million. (Source: National Center for Biotechnology Information)

Furthermore, effective storage of vaccines is a major concern by manufacturers throughout the supply chain for veterinary vaccines. Immunobiologicals are stored more in cooler temperatures using deep freezing and should remain at this temperature during storage and transportation, until it gets to the animals to be vaccinated. A slight fault in the storing of vaccines may cost a thousand dollars in terms of wastage of those vaccines and then resuscitators. These factors could limit veterinary vaccines market’s potential for overall growth.

 

OPPORTUNITY: Untapped growth potential in emerging markets

Companion animal ownership has grown significantly worldwide. This is most evidenced in developing markets in Asia and Latin America, where urbanization and increased disposable incomes have made animal health more accessible and facilitated pet owners' higher spending on care. Emerging countries like India and China have large livestock markets. As per the report of Basic Animal Husbandry Statistics, 2024, the total milk production estimate for India during 2023-24 is 239.30 million tonnes, showing an increase of 5.62% concerning the previous decade and from 146.3 million tonnes in 2014-15. Also, there has been an increment in milk production of 3.78% in 2023-24 over the previous year.

On the other hand, China is the largest meat producer globally: overall for one year, in 2023, China's total meat production reached 97 million tons, with an increase of 4.5%. While meat consumption increased to 102 million tons, marking an increase of 4.1%. Emerging economies are expected to be the centers of focus for the growth of veterinary vaccines markets. The Asia Pacific, Middle Eastern, and Latin American regions are relatively untapped markets for companies compared to Europe and North America. These emerging countries have large poultry and dairy animal populations that are expected to drive the growth of the veterinary health market. Industrially, they are increasing the number of veterinarians each day. Most of the emerging veterinary practices have integrated advanced technological solutions common among veterinarians of developed economies. Hence, along with a rapid increase in their companion animal population and growing demand for livestock, collectively, these factors are expected to create numerous opportunities for the veterinary vaccines market in emerging economies.

CHALLENGES: Limited awareness & training and shortage of veterinarian in low-income countries

Major hurdles exist in the business of veterinary vaccinations due to illiteracy and lack of indepth professionals in developing countries. In most impoverished and rural communities, issues of social adoption and much awareness about the merits of immunization were among the leading causes of low program uptake. The global shortage of qualified veterinarians and animal health professionals is another hindrance, even for developing countries, in the effective distribution and execution of these projects. Many low-income countries are suffering from a critical shortage of veterinarians. For example, as per the information given in the 2024 report by Federation of Veterinarians of Europe, there is shortage of veterinary professionals, especially in rural areas and farm veterinary practice. Bulgaria possesses around 2200 practitioners, out of which, around 900 work in farm animal practice. The remaining 65-75% are either close to or have already retired. Zimbabwe has only about 340 veterinarians for its population. Tanzania has around 725 veterinarians with a population of over 56 million people. Mauritania includes only less than 127 veterinarians who are available for a vast area. (source: Vetclick News)

In addition to this, there are other challenges that hinder the training of sufficient veterinary professionals to meet demand. For example, in countries like China, over 10,000 vet graduates enter the job market annually, yet most drop out of the vicious cycle of underpaid and poorly resourced veterinary jobs. Similar trends are prevalent in other developing countries, where the economic viability of practicing as a veterinarian is in doubt. (source: Sixth Tone). Combined, these elements restrict the reach and impact of vaccination accessibility and hence slow the market expansion and even less disease prevention in those areas needing it the most.

Global Veterinary Vaccines Market Ecosystem Analysis

The ecosystem market map of the veterinary vaccines includes manufacturers, distributors, research and development organizations, and end users. Manufacturers include the organizations that are involved in the entire process of research, product development, optimization, and launch. Distributors include third parties and e-commerce sites that are linked with the organization for the marketing of veterinary vaccines. Research and product development include in-house research facilities, contract research organizations, and contract development and manufacturing organizations that play a key role in outsourcing services for product development to manufacturers. End users include the areas where these veterinary vaccines are adopted for final production.

Veterinary Vaccines Market
 

By type, the livestock vaccines is expected to be the largest segment during the forecast period.

In 2023, the livestock vaccines segment held the largest share of the veterinary vaccines market. As livestock animals are owned for the production of food, such as meat and dairy products. As global demand for animal derived food increases and livestock farming intensifies to meet the nutritional needs of an expanding population, there is a greater emphasis on maintaining animal health, preventing disease outbreaks, and improving overall productivity. The meat industry is experiencing significant growth, driven by both increased production capacity and rising domestic and global demand for meat products. In 2023, the United States claims the global title of the largest beef producer, with over 30% of its farms dedicated to beef production. (source: Carlisle technology). As livestock farming grows more industrialized and regulated, there will be greater needs for disease preventive vaccines.

Furthermore, the rising government laws and policies on vaccination for livestock, along with the increasing awareness of food safety and animal health, will drive the need in the future for livestock vaccines. All these factors combine to ensure that livestock vaccines continue to remain the largest segment for veterinary vaccines.

By end user, veterinary hospitals segment is expected to hold the largest share during the forecast period.

In 2023, the market for veterinary vaccines was dominated by veterinary hospitals by end user segment. Increased ownership to companion animals, increased population of livestock animals, and demand for animal derived food in emerging economies would therefore lead to an increasing emphasis on animal healthcare and vaccination. Animal Care has improved remarkably for the interiors in veterinary hospitals as the first source of care for diagnosing and treating any healthcare condition.

Most veterinary vaccine manufacturers prefer to sell their vaccines directly to licenced veterinarians or to proprietary distributors who only sell to veterinarians, rather than to third-party pharmacies. Such availability of many veterinary professionals in veterinary hospitals, increasing veterinary visits, and increasing awareness about animal health in developing emerging countries are other contributing factors.

Also, increased spending on animal care has been another driver behind the increase in vaccination levels in hospitals for pets. This trend is mostly observed in the developed parts of the world such as the US, Germany, and the UK. Pet owners in these parts are willing to spend on their pets' regular health checkup and treatment. For example, the American Pet Products Association says that the U.S. market spent USD 147 billion on pets in 2023, including USD 64.4 billion on food and treats. Vet care and product sales cost around USD 38.3 billion while other services, such as grooming, accounted for USD 12.3 billion.

The veterinary sector in the emerging countries is growing because of the rapid increase in the population of companion animals and livestock, along with rising affordability in these countries for healthcare services.

By region, Asia pacific will be the fastest growing region during the forecast period.

Among all the regions in the globe, the Asia Pacific is the fastest growing in the veterinary vaccines market. Pet ownership in countries like China, India, is one of the reasons increasing the demand for veterinary care services, including vaccinations. Animal health, for pets as well as for production animals, is increasing demand for preventive healthcare, such as vaccinations. Increasing economic growth and the rising disposable income in the region are also causes of the demand for veterinary services and products. For instance, the consumption of various meat products, such as beef, pork, poultry, and mutton, is much higher in China than in other APAC countries. According to the Food and Agriculture Organization (FAO), total pork consumption in China was 40,698.6 metric tons in 2000; this figure is estimated to increase to 62,748.6 metric tons by 2030. The increase in pork & beef consumption and exports is expected to drive the utilization of animal healthcare products by livestock producers, thus contributing directly to market growth.

Besides, the increasing scale of industrialized farming makes health of livestock very important to ensure food security in the region for this is driving the need for proper vaccines to avert such diseases. Focus on improvement to animal health through vaccination advocacy by regulations and initiatives is what has been in place by the governments in the region.

Thus increase in pet ownership, improving veterinary infrastructure, and an increasing focus by governments on improving livestock health all propelling growing in this region.

HIGHEST CAGR MARKET IN 2023
CHINA FASTEST GROWING MARKET IN THE REGION
Veterinary Vaccines Market

Recent Developments of Veterinary Vaccines Market

  • In November 2024, Ceva (France) Invested in New Vaccine Manufacturing Plant in Monor, Hungary. This development will establish a 7,000 m2 plant in Monor, with the most advanced technologies, where Ceva will produce fermentation-based multicomponent inactivated vaccines for animals that will help expand its global production capacity
  • In November 2024, Boehringer Ingelheim International GmbH (Germany)launched EURICAN L4 vaccine, to protect dogs against the growing threat of leptospirosis, a severe and reemerging infectious disease.
  • In September 2024, Merck & Co., Inc. (US ) announced the expansion of its NOBIVAC NXT platform with the launch of a groundbreaking new vaccine for Feline Leukemia Virus (FeLV). This vaccine is the first and only to incorporate RNA-Particle Technology, offering a novel alternative for feline FeLV prevention
  • In March 2024, Zoetis (US) announced the purchase of a manufacturing site in Melbourne, Ausralia to significantly expand its current operations at the site and increase future capabilities to develop and manufacture vaccines for sheep, cattle, dogs, cats and horses

Key Market Players

Want to explore hidden markets that can drive new revenue in Veterinary Vaccines Market?

Scope of the Report

Report Metric Details
Market size available for years 2024-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Value (USD Million/Billion)
Segments covered by type, disease, technology, route of administration, end user
Geographies covered North America (US & Canada), Europe (Germany, the UK, France, Italy, Spain, Netherlands and RoE), APAC (Japan, China, Australia, South Korea, India, New Zealand and the RoAPAC), LATAM (Brazil, Mexico, and RoLATAM), and MEA (GCC Countries {United Arab Emirates (UAE), Kingdom of Saudi Arabia (KSA), Rest of GCC countries}, RoMEA)

 

Key Questions Addressed by the Report

What are the key drivers for the veterinary vaccines market?
The market for veterinary vaccines is driven by the increasing pet population and pet ownership. Growing incidence of infectious diseases and initiatives by government to improve animal health are key factors to propel the market during the forecast period.
Which type segment in the veterinary vaccines market provides the most opportunity for growth?
The companion animal segment is growing at a faster pace within the veterinary vaccines market due to several key factors. As pets are increasingly seen as family members, pet owners are becoming more focused on preventive healthcare to ensure their animals remain healthy. This growing awareness of animal health, coupled with rising disposable incomes, especially in developed regions, is driving the demand for veterinary services, including vaccinations.
Which end user segment provides the most opportunity for growth?
Veterinary hospitals are growing at a higher rate within the veterinary vaccines market due to several key factors. As pets become more integrated into families, pet owners are seeking higher-quality, specialized care for their animals, leading to increased demand for veterinary hospitals. These hospitals offer comprehensive services, including advanced vaccination programs, preventive care, diagnostics, and treatment of complex health issues.
What are the main vendors present in this market?
The main vendors in the market are Zoetis(US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco (US), Virbac (France), Ceva (France), Phibro Animal Health Corporation (US), Hester Biosciences Limited (India), and Neogen Corporation (US).
Which region is expected to witness the highest demand growth for veterinary vaccines in the coming years?
Asia Pacific is poised for significant growth in the veterinary vaccines market, driven by increasing pet ownership, rising awareness of animal health, and growing demand for livestock protection. Economic growth, improved veterinary infrastructure, and expanding adoption of veterinary services in emerging economies like China and India are further fueling market expansion in the region.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Veterinary Vaccines Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
33
RESEARCH METHODOLOGY
38
EXECUTIVE SUMMARY
52
PREMIUM INSIGHTS
57
MARKET OVERVIEW
60
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Rise in companion animal population and pet ownership
    - Increasing incidence of infectious zoonotic diseases
    - Favorable initiatives by government agencies and animal associations
    - Growing demand for animal-derived food products
    - Increased adoption of pet insurance and high animal health expenditure
    RESTRAINTS
    - High cost of vaccine development
    OPPORTUNITIES
    - Technological advancements for veterinary vaccine development
    - Untapped growth potential in emerging economies
    CHALLENGES
    - Limited awareness about animal vaccines and shortage of trained veterinarians in low-income countries
    - Stringent regulatory requirements for licensing veterinary vaccines
  • 5.3 INDUSTRY TRENDS
  • 5.4 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Recombinant DNA technology
    - mRNA-based vaccines
    COMPLEMENTARY TECHNOLOGIES
    - Vaccine adjuvant technology
    - Needle-free and microneedle technology
    ADJACENT TECHNOLOGIES
    - Genome editing technology
  • 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 VALUE CHAIN ANALYSIS
  • 5.8 TRADE ANALYSIS
    IMPORT DATA FOR HS CODE 300242
    EXPORT DATA FOR HS CODE 300230
  • 5.9 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    KEY BUYING CRITERIA
  • 5.11 REGULATORY ANALYSIS
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATORY FRAMEWORK
    - North America
    - Europe
    - Rest of the World
  • 5.12 PATENT ANALYSIS
    JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.13 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY KEY PLAYER, 2021–2023
    AVERAGE SELLING PRICE TREND, BY REGION, 2021–2023
  • 5.14 KEY CONFERENCES & EVENTS, 2024–2026
  • 5.15 ECOSYSTEM ANALYSIS
  • 5.16 CASE STUDY ANALYSIS
  • 5.17 REIMBURSEMENT ANALYSIS
  • 5.18 UNMET NEEDS/END-USER EXPECTATIONS
  • 5.19 IMPACT OF AI/GEN AI ON VETERINARY VACCINES MARKET
  • 5.20 INVESTMENT & FUNDING SCENARIO
  • 5.21 PIPELINE ANALYSIS
VETERINARY VACCINES MARKET, BY TYPE
101
  • 6.1 INTRODUCTION
  • 6.2 LIVESTOCK VACCINES
    BOVINE VACCINES
    - Increasing demand for meat and milk to drive market
    SMALL RUMINANT VACCINES
    - Increased livestock population and favorable government initiatives to propel market growth
  • 6.3 PORCINE VACCINES
    GROWING AWARENESS ABOUT ANIMAL VACCINATION TO SUPPORT MARKET GROWTH
  • 6.4 POULTRY VACCINES
    HIGH NEED FOR PROTEIN IN DAILY DIET TO AUGMENT MARKET GROWTH
  • 6.5 COMPANION ANIMAL VACCINES
    CANINE VACCINES
    - Increasing number of pet dogs and growing prevalence of zoonotic diseases to spur market growth
    FELINE VACCINES
    - Rising adoption of cats and growing need for better veterinary care to boost market growth
  • 6.6 AQUACULTURE VACCINES
    INCREASED POPULARITY OF COMMERCIAL FISH FARMING TO FUEL MARKET GROWTH
  • 6.7 OTHER VETERINARY VACCINES
VETERINARY VACCINES MARKET, BY DISEASE
122
  • 7.1 INTRODUCTION
  • 7.2 LIVESTOCK DISEASES
    BOVINE DISEASES
    - Favorable government programs and increased awareness about animal health in emerging economies to aid market growth
    SMALL RUMINANT DISEASES
    - New vaccine formulations and improved delivery methods to propel vaccine demand for small ruminants
  • 7.3 PORCINE DISEASES
    INCREASED FOCUS ON LARGE-SCALE INDUSTRIAL BREEDING OF PIGS TO AID MARKET GROWTH
  • 7.4 POULTRY DISEASES
    ONGOING RISK OF AVIAN INFLUENZA OUTBREAKS TO SPUR NEED FOR POULTRY VACCINES
  • 7.5 COMPANION ANIMAL DISEASES
    CANINE DISEASES
    - Rise in pet ownership in emerging economies to boost market growth
    FELINE DISEASES
    - Rise in cat population in urban areas to drive demand for feline disease management programs
  • 7.6 AQUACULTURE DISEASES
    NEED FOR PREVENTIVE HEALTHCARE AND BIOSECURITY TO SUPPORT MARKET GROWTH
  • 7.7 OTHER VETERINARY DISEASES
VETERINARY VACCINES MARKET, BY TECHNOLOGY
144
  • 8.1 INTRODUCTION
  • 8.2 LIVE ATTENUATED VACCINES
    EASE OF ADMINISTRATION AND LONG-TERM IMMUNITY TO SUPPORT MARKET GROWTH
  • 8.3 INACTIVATED VACCINES
    NEED TO DEVELOP ARTIFICIAL IMMUNITY FROM NON-LIVING PATHOGENS TO DRIVE MARKET
  • 8.4 TOXOID VACCINES
    TOXOID VACCINES TO STIMULATE IMMUNE SYSTEM AND PROTECT ANIMALS FROM BACTERIAL TOXINS
  • 8.5 RECOMBINANT VACCINES
    BETTER STABILITY, HIGHER SAFETY, AND NO POST-VACCINATION REACTIONS TO SUPPORT VACCINE ADOPTION
  • 8.6 OTHER VACCINE TECHNOLOGIES
VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION
155
  • 9.1 INTRODUCTION
  • 9.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION
    EASE OF ADMINISTRATION, REDUCED PAIN, AND LOWER RISK OF TISSUE DAMAGE TO AID MARKET GROWTH
  • 9.3 INTRAMUSCULAR ROUTE OF ADMINISTRATION
    BETTER IMMUNE RESPONSE AND LOWER RATE OF INJECTION-SITE REACTIONS TO AUGMENT MARKET GROWTH
  • 9.4 ORAL ROUTE OF ADMINISTRATION
    COST-EFFECTIVENESS, INCREASED SAFETY, AND HIGH PATIENT ACCEPTABILITY TO SUPPORT MARKET GROWTH
  • 9.5 INTRANASAL/SPRAY ROUTE OF ADMINISTRATION
    COST-EFFECTIVENESS AND RAPID ABSORPTION OF MEDICINE TO AID IN MASS VACCINATION
  • 9.6 INTRAOCULAR ROUTE OF ADMINISTRATION
    SIMPLE ADMINISTRATION OF VACCINES IN LARGE-SCALE FARMING OPERATIONS TO AID MARKET GROWTH
  • 9.7 OTHER ROUTES OF ADMINISTRATION
VETERINARY VACCINES MARKET, BY END USER
171
  • 10.1 INTRODUCTION
  • 10.2 VETERINARY HOSPITALS
    GROWING AWARENESS ABOUT ANIMAL HEALTH AND INCREASING VETERINARY EXPENDITURE BY PET OWNERS TO DRIVE MARKET
  • 10.3 VETERINARY CLINICS
    RISING NUMBER OF PET VISITS TO PRIVATE CLINICS TO SPUR MARKET GROWTH
  • 10.4 OTHER END USERS
VETERINARY VACCINES MARKET, BY REGION
177
  • 11.1 INTRODUCTION
  • 11.2 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Increasing companion animal population and growing incidence of zoonotic diseases to drive market
    JAPAN
    - High consumption of animal-derived products and increased pet health expenditure to propel market growth
    INDIA
    - Growth in poultry industry and high demand for dairy products to augment market growth
    AUSTRALIA
    - Increase in per capita income and rise in meat consumption to aid market growth
    SOUTH KOREA
    - High demand for animal protein and favorable government subsidies for meat production to spur market growth
    NEW ZEALAND
    - Favorable government initiatives and increased incidence of livestock diseases to boost market growth
    REST OF ASIA PACIFIC
  • 11.3 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - US to dominate North American veterinary vaccines market during forecast period
    CANADA
    - Rising pet ownership and increasing chicken consumption to drive demand for veterinary vaccines
  • 11.4 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Increased poultry consumption and high pet healthcare expenditure to drive market
    UK
    - Rising adoption of pets to augment market growth
    FRANCE
    - Rising companion animal and livestock population to boost market growth
    ITALY
    - Better availability of pet products through large-scale outlets to augment market growth
    SPAIN
    - Increase in veterinary practices and willingness to spend on animal healthcare to drive market
    NETHERLANDS
    - High demand for meat and increased pressure on sustainable farming practices to fuel market growth
    REST OF EUROPE
  • 11.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Well-established livestock industry to promote market growth
    MEXICO
    - Focus on pork and poultry meat production to fuel market growth
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    GCC COUNTRIES
    - Kingdom of Saudi Arabia
    - UAE
    - Rest of GCC countries
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
308
  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
  • 12.3 REVENUE ANALYSIS, 2019–2023
  • 12.4 MARKET SHARE ANALYSIS, 2023
    RANKING OF KEY MARKET PLAYERS, 2O23
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Region footprint
    - Type footprint
    - Disease footprint
    - Technology footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 12.7 BRAND/PRODUCT COMPARISON
  • 12.8 R&D EXPENDITURE OF KEY PLAYERS
  • 12.9 COMPANY VALUATION & FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 12.10 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & APPROVALS
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
COMPANY PROFILES
329
  • 13.1 KEY PLAYERS
    MERCK & CO., INC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    ZOETIS
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    ELANCO
    - Business overview
    - Products offered
    - Recent developments
    CEVA
    - Business overview
    - Products offered
    - Recent developments
    VIRBAC
    - Business overview
    - Products offered
    - Recent developments
    PHIBRO ANIMAL HEALTH CORPORATION
    - Business overview
    - Products offered
    HESTER BIOSCIENCES LIMITED
    - Business overview
    - Products offered
    - Recent developments
    NEOGEN CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    HIPRA
    - Business overview
    - Products offered
    - Recent developments
    BIOGÉNESIS BAGÓ
    - Business overview
    - Products offered
    - Recent developments
    TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.
    - Business overview
    - Products offered
    - Recent developments
    CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.
    - Business overview
    - Products offered
    JINYU BIO-TECHNOLOGY CO., LTD.
    - Business overview
    - Products offered
    - Recent developments
    VAXXINOVA INTERNATIONAL B.V.
    - Business overview
    - Products offered
    - Recent developments
  • 13.2 OTHER COMPANIES
    ENDOVAC ANIMAL HEALTH
    BRILLIANT BIO PHARMA
    APTIMMUNE
    INDIAN IMMUNOLOGICALS LTD.
    TORIGEN PHARMACEUTICALS INC.
    INTAS PHARMACEUTICALS LTD.
    OUROFINO ANIMAL HEALTH
    BIOVAC LTD.
    LABORATOIRE LCV
    KYORITSU SEIYAKU CORPORATION
APPENDIX
397
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 VETERINARY VACCINES MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 STANDARD CURRENCY CONVERSION RATES
  • TABLE 3 VETERINARY VACCINES MARKET: STUDY ASSUMPTIONS
  • TABLE 4 VETERINARY VACCINES MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 5 PET (DOGS AND CATS) OWNERSHIP IN US, 2024
  • TABLE 6 MAJOR OUTBREAKS OF ZOONOTIC DISEASES, 2022–2023
  • TABLE 7 PAST AND PROJECTED TRENDS IN CONSUMPTION OF MEAT AND MILK IN DEVELOPED COUNTRIES
  • TABLE 8 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
  • TABLE 9 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
  • TABLE 10 KEY COMMERCIAL PRODUCTS USING RECOMBINANT DNA TECHNOLOGY
  • TABLE 11 IMPORT DATA FOR HS CODE 300230, BY COUNTRY, 2019–2023 (USD THOUSAND)
  • TABLE 12 EXPORT VALUE FOR HS CODE 300230, BY COUNTRY, 2019–2023 (USD THOUSAND)
  • TABLE 13 VETERINARY VACCINES MARKET: PORTER’S FIVE FORCES
  • TABLE 14 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF VETERINARY VACCINES, BY END USER
  • TABLE 15 KEY BUYING CRITERIA FOR END USERS
  • TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 VETERINARY VACCINES MARKET: LIST OF GRANTED PATENTS, 2022–2023
  • TABLE 20 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY KEY PLAYER, 2021–2023
  • TABLE 21 AVERAGE SELLING PRICE TREND OF CANINE VACCINES (PER DOSE), BY REGION, 2021–2023
  • TABLE 22 AVERAGE SELLING PRICE TREND OF LIVESTOCK VACCINES (PER DOSE) BY REGION, 2021–2023
  • TABLE 23 VETERINARY VACCINES MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2024–DECEMBER 2026
  • TABLE 24 VETERINARY VACCINES MARKET: ROLE IN ECOSYSTEM
  • TABLE 25 CASE STUDY 1: SUPPORTING INNOVATION IN LIVESTOCK VACCINES
  • TABLE 26 CASE STUDY 2: IMPACT OF A19 VACCINATION ON LIVESTOCK HEALTH AND PRODUCTIVITY
  • TABLE 27 CASE STUDY 3: DEVELOPMENT OF CANINE VACCINES FOR VALLEY FEVER
  • TABLE 28 VETERINARY VACCINES MARKET: UNMET NEEDS/END-USER EXPECTATIONS
  • TABLE 29 VETERINARY VACCINES MARKET: PIPELINE ANALYSIS
  • TABLE 30 VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 31 LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 32 LIVESTOCK VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 33 COMMERCIAL BOVINE VACCINES BY KEY MANUFACTURERS
  • TABLE 34 BOVINE VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 35 COMMERCIAL SMALL RUMINANT VACCINES BY KEY MANUFACTURERS
  • TABLE 36 SMALL RUMINANT VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 37 COMMERCIAL PORCINE VACCINES BY KEY MANUFACTURERS
  • TABLE 38 PORCINE VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 39 COMMERCIAL POULTRY VACCINES BY KEY MANUFACTURERS
  • TABLE 40 POULTRY VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 41 COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 42 COMPANION ANIMAL VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 43 COMMERCIAL CANINE VACCINES BY KEY MANUFACTURERS
  • TABLE 44 CANINE VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 45 COMMERCIAL FELINE VACCINES BY KEY MANUFACTURERS
  • TABLE 46 FELINE VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 47 COMMERCIAL AQUACULTURE VACCINES BY KEY MANUFACTURERS
  • TABLE 48 AQUACULTURE VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 49 OTHER COMMERCIAL VETERINARY VACCINES BY KEY MANUFACTURERS
  • TABLE 50 OTHER VETERINARY VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 51 VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 52 VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 53 VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 54 BOVINE DISEASES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 55 SMALL RUMINANT DISEASES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 56 VETERINARY VACCINES MARKET FOR PORCINE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 57 VETERINARY VACCINES MARKET FOR POULTRY DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 58 VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 59 VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 60 CANINE DISEASES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 61 FELINE DISEASES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 62 VETERINARY VACCINES MARKET FOR AQUACULTURE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 63 VETERINARY VACCINES MARKET FOR OTHER VETERINARY DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 64 VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 65 COMMERCIALLY AVAILABLE KEY LIVE ATTENUATED VACCINES
  • TABLE 66 LIVE ATTENUATED VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 67 COMMERCIALLY AVAILABLE KEY INACTIVATED VACCINES
  • TABLE 68 INACTIVATED VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 69 COMMERCIALLY AVAILABLE KEY TOXOID VACCINES
  • TABLE 70 TOXOID VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 71 COMMERCIALLY AVAILABLE KEY RECOMBINANT VACCINES
  • TABLE 72 RECOMBINANT VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 73 COMMERCIALLY AVAILABLE OTHER KEY VACCINE TECHNOLOGIES
  • TABLE 74 OTHER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 75 ROUTES OF ADMINISTRATION FOR MAJOR VETERINARY VACCINES, BY KEY PLAYER
  • TABLE 76 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 77 COMMERCIALLY AVAILABLE VACCINES WITH SUBCUTANEOUS ROUTE OF ADMINISTRATION
  • TABLE 78 VETERINARY VACCINES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 79 COMMERCIALLY AVAILABLE VACCINES WITH INTRAMUSCULAR ROUTE OF ADMINISTRATION
  • TABLE 80 VETERINARY VACCINES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 81 COMMERCIALLY AVAILABLE VACCINES WITH ORAL ROUTE OF ADMINISTRATION
  • TABLE 82 VETERINARY VACCINES MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 83 COMMERCIALLY AVAILABLE VACCINES WITH INTRANASAL/SPRAY ROUTE OF ADMINISTRATION
  • TABLE 84 VETERINARY VACCINES MARKET FOR INTRANASAL/SPRAY ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 85 COMMERCIALLY AVAILABLE VACCINES WITH INTRAOCULAR ROUTE OF ADMINISTRATION
  • TABLE 86 VETERINARY VACCINES MARKET FOR INTRAOCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 87 COMMERCIALLY AVAILABLE VACCINES WITH OTHER ROUTES OF ADMINISTRATION
  • TABLE 88 VETERINARY VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 89 VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 90 VETERINARY HOSPITALS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 91 VETERINARY CLINICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 92 OTHER END USERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 93 VETERINARY VACCINES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 94 PORCINE VACCINES MARKET, BY REGION, 2022–2029 (MILLION UNITS)
  • TABLE 95 POULTRY VACCINES MARKET, BY REGION, 2022–2029 (MILLION UNITS)
  • TABLE 96 BOVINE VACCINES MARKET, BY REGION, 2022–2029 (MILLION UNITS)
  • TABLE 97 SMALL RUMINANT VACCINES MARKET, BY REGION, 2022–2029 (MILLION UNITS)
  • TABLE 98 CANINE VACCINES MARKET, BY REGION, 2022–2029 (MILLION UNITS)
  • TABLE 99 FELINE VACCINES MARKET, BY REGION, 2022–2029 (MILLION UNITS)
  • TABLE 100 AQUACULTURE VACCINES MARKET, BY REGION, 2022–2029 (MILLION UNITS)
  • TABLE 101 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 103 ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 104 ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 105 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 106 ASIA PACIFIC: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 107 ASIA PACIFIC: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 108 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 111 NUMBER OF VETERINARIANS IN KEY ASIA PACIFIC COUNTRIES, 2022
  • TABLE 112 CHINA: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 113 CHINA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 114 CHINA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 115 CHINA: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 116 CHINA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 117 CHINA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 118 CHINA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 119 CHINA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 120 CHINA: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 121 JAPAN: PRODUCTION AND CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2000 VS. 2030 (THOUSAND METRIC TONS)
  • TABLE 122 JAPAN: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 123 JAPAN: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 124 JAPAN: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 125 JAPAN: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 126 JAPAN: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 127 JAPAN: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 128 JAPAN: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 129 JAPAN: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 130 JAPAN: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 131 INDIA: PRODUCTION AND CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2000 VS. 2030 (THOUSAND METRIC TONS)
  • TABLE 132 INDIA: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 133 INDIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 134 INDIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 135 INDIA: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 136 INDIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 137 INDIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 138 INDIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 139 INDIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 140 INDIA: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 141 AUSTRALIA: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 142 AUSTRALIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 143 AUSTRALIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 144 AUSTRALIA: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 145 AUSTRALIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 146 AUSTRALIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 147 AUSTRALIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 148 AUSTRALIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 149 AUSTRALIA: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 150 SOUTH KOREA: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 151 SOUTH KOREA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 152 SOUTH KOREA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 153 SOUTH KOREA: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 154 SOUTH KOREA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 155 SOUTH KOREA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 156 SOUTH KOREA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 157 SOUTH KOREA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 158 SOUTH KOREA: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 159 NEW ZEALAND: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 160 NEW ZEALAND: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 161 NEW ZEALAND: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 162 NEW ZEALAND: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 163 NEW ZEALAND: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 164 NEW ZEALAND: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 165 NEW ZEALAND: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 166 NEW ZEALAND: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 167 NEW ZEALAND: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 168 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 169 REST OF ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 170 REST OF ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 171 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 172 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 173 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 174 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 175 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 176 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 177 NORTH AMERICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 178 NORTH AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 179 NORTH AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 180 NORTH AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 181 NORTH AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 182 NORTH AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 183 NORTH AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 184 NORTH AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 185 NORTH AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 186 NORTH AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 187 NUMBER OF VETERINARIANS IN US AND CANADA, 2022
  • TABLE 188 PET INDUSTRY EXPENDITURE IN US, 2018–2024 (USD BILLION)
  • TABLE 189 US: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 190 US: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 191 US: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 192 US: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 193 US: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 194 US: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 195 US: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 196 US: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 197 US: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 198 CANADA: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 199 CANADA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 200 CANADA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 201 CANADA: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 202 CANADA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 203 CANADA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 204 CANADA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 205 CANADA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 206 CANADA: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 207 EUROPE: VETERINARY VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 208 EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 209 EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 210 EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 211 EUROPE: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 212 EUROPE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 213 EUROPE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 214 EUROPE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 215 EUROPE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 216 EUROPE: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 217 NUMBER OF VETERINARIANS IN EUROPE, 2022
  • TABLE 218 GERMANY: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 219 GERMANY: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 220 GERMANY: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 221 GERMANY: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 222 GERMANY: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 223 GERMANY: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 224 GERMANY: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 225 GERMANY: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 226 GERMANY: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 227 PET POPULATION IN UK, 2024
  • TABLE 228 UK: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 229 UK: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 230 UK: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 231 UK: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 232 UK: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 233 UK: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 234 UK: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 235 UK: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 236 UK: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 237 FRANCE: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 238 FRANCE: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 239 FRANCE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 240 FRANCE: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 241 FRANCE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 242 FRANCE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 243 FRANCE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 244 FRANCE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 245 FRANCE: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 246 ITALY: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 247 ITALY: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 248 ITALY: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 249 ITALY: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 250 ITALY: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 251 ITALY: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 252 ITALY: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 253 ITALY: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 254 ITALY: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 255 SPAIN: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 256 SPAIN: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 257 SPAIN: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 258 SPAIN: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 259 SPAIN: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 260 SPAIN: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 261 SPAIN: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 262 SPAIN: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 263 SPAIN: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 264 NETHERLANDS: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 265 NETHERLANDS: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 266 NETHERLANDS: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 267 NETHERLANDS: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 268 NETHERLANDS: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 269 NETHERLANDS: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 270 NETHERLANDS: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 271 NETHERLANDS: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 272 NETHERLANDS: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 273 REST OF EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 274 REST OF EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 275 REST OF EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 276 REST OF EUROPE: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 277 REST OF EUROPE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 278 REST OF EUROPE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 279 REST OF EUROPE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 280 REST OF EUROPE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 281 REST OF EUROPE: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 282 LATIN AMERICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 283 LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 284 LATIN AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 285 LATIN AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 286 LATIN AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 287 LATIN AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 288 LATIN AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 289 LATIN AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 290 LATIN AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 291 LATIN AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 292 BRAZIL: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 293 BRAZIL: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 294 BRAZIL: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 295 BRAZIL: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 296 BRAZIL: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 297 BRAZIL: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 298 BRAZIL: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 299 BRAZIL: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 300 BRAZIL: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 301 MEXICO: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 302 MEXICO: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 303 MEXICO: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 304 MEXICO: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 305 MEXICO: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 306 MEXICO: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 307 MEXICO: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 308 MEXICO: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 309 MEXICO: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 310 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 311 REST OF LATIN AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 312 REST OF LATIN AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 313 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 314 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 315 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 316 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 317 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 318 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 319 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 320 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 321 MIDDLE EAST & AFRICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 322 MIDDLE EAST & AFRICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 323 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 324 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 325 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 326 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 327 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 328 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 329 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 330 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 331 GCC COUNTRIES: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 332 GCC COUNTRIES: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 333 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 334 GCC COUNTRIES: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 335 GCC COUNTRIES: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 336 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 337 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 338 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 339 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 340 KINGDOM OF SAUDI ARABIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 341 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 342 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 343 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 344 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 345 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 346 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 347 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 348 UAE: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 349 UAE: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 350 UAE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 351 UAE: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 352 UAE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 353 UAE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 354 UAE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 355 UAE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 356 UAE: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 357 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 358 REST OF GCC COUNTRIES: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 359 REST OF GCC COUNTRIES: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 360 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 361 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 362 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 363 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 364 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 365 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 366 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 367 REST OF MIDDLE EAST & AFRICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 368 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 369 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 370 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 371 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 372 REST OF MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 373 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
  • TABLE 374 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 375 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VETERINARY VACCINES MARKET
  • TABLE 376 VETERINARY VACCINES MARKET: DEGREE OF COMPETITION
  • TABLE 377 VETERINARY VACCINES MARKET: REGION FOOTPRINT
  • TABLE 378 VETERINARY VACCINES MARKET: TYPE FOOTPRINT
  • TABLE 379 VETERINARY VACCINES MARKET: DISEASE FOOTPRINT
  • TABLE 380 VETERINARY VACCINES MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 381 VETERINARY VACCINES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 382 VETERINARY VACCINES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 383 VETERINARY VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 384 VETERINARY VACCINES MARKET: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 385 VETERINARY VACCINES MARKET: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 386 VETERINARY VACCINES MARKET: OTHER DEVELOPMENTS, JANUARY 2021–DECEMBER 2024
  • TABLE 387 MERCK & CO., INC.: COMPANY OVERVIEW
  • TABLE 388 MERCK & CO., INC.: PRODUCTS OFFERED
  • TABLE 389 MERCK & CO., INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 390 MERCK & CO., INC.: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 391 MERCK & CO., INC.: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 392 MERCK & CO., INC.: OTHER DEVELOPMENTS, JANUARY 2021− DECEMBER 2024
  • TABLE 393 ZOETIS: COMPANY OVERVIEW
  • TABLE 394 ZOETIS: PRODUCTS OFFERED
  • TABLE 395 ZOETIS: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024
  • TABLE 396 ZOETIS: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 397 ZOETIS: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 398 ZOETIS: OTHER DEVELOPMENTS, JANUARY 2021–DECEMBER 2024
  • TABLE 399 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
  • TABLE 400 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED
  • TABLE 401 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024
  • TABLE 402 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 403 ELANCO: COMPANY OVERVIEW
  • TABLE 404 ELANCO: PRODUCTS OFFERED
  • TABLE 405 ELANCO: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 406 CEVA: COMPANY OVERVIEW
  • TABLE 407 CEVA: PRODUCTS OFFERED
  • TABLE 408 CEVA: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 409 CEVA: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 410 VIRBAC: COMPANY OVERVIEW
  • TABLE 411 VIRBAC: PRODUCTS OFFERED
  • TABLE 412 VIRBAC: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024
  • TABLE 413 VIRBAC: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 414 VIRBAC: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 415 VIRBAC: OTHER DEVELOPMENTS, JANUARY 2021–DECEMBER 2024
  • TABLE 416 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY OVERVIEW
  • TABLE 417 PHIBRO ANIMAL HEALTH CORPORATION: PRODUCTS OFFERED
  • TABLE 418 HESTER BIOSCIENCES LIMITED: COMPANY OVERVIEW
  • TABLE 419 HESTER BIOSCIENCES LIMITED: PRODUCTS OFFERED
  • TABLE 420 HESTER BIOSCIENCES LIMITED: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 421 NEOGEN CORPORATION: COMPANY OVERVIEW
  • TABLE 422 NEOGEN CORPORATION: PRODUCTS OFFERED
  • TABLE 423 NEOGEN CORPORATION: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 424 HIPRA: COMPANY OVERVIEW
  • TABLE 425 HIPRA: PRODUCTS OFFERED
  • TABLE 426 HIPRA: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024
  • TABLE 427 BIOGÉNESIS BAGÓ: COMPANY OVERVIEW
  • TABLE 428 BIOGÉNESIS BAGÓ: PRODUCTS OFFERED
  • TABLE 429 BIOGÉNESIS BAGÓ: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 430 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: COMPANY OVERVIEW
  • TABLE 431 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: PRODUCTS OFFERED
  • TABLE 432 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 433 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.: COMPANY OVERVIEW
  • TABLE 434 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.: PRODUCTS OFFERED
  • TABLE 435 JINYU BIO-TECHNOLOGY CO., LTD.: COMPANY OVERVIEW
  • TABLE 436 JINYU BIO-TECHNOLOGY CO., LTD.: PRODUCTS OFFERED
  • TABLE 437 JINYU BIO-TECHNOLOGY CO., LTD.: PRODUCT APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 438 VAXXINOVA INTERNATIONAL B.V.: COMPANY OVERVIEW
  • TABLE 439 VAXXINOVA INTERNATIONAL B.V.: PRODUCTS OFFERED
  • TABLE 440 VAXXINOVA INTERNATIONAL B.V.: PRODUCT APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 441 VAXXINOVA INTERNATIONAL B.V.: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 442 ENDOVAC ANIMAL HEALTH: COMPANY OVERVIEW
  • TABLE 443 BRILLIANT BIO PHARMA: COMPANY OVERVIEW
  • TABLE 444 APTIMMUNE: COMPANY OVERVIEW
  • TABLE 445 INDIAN IMMUNOLOGICALS LTD.: COMPANY OVERVIEW
  • TABLE 446 TORIGEN PHARMACEUTICALS INC.: COMPANY OVERVIEW
  • TABLE 447 INTAS PHARMACEUTICALS LTD.: COMPANY OVERVIEW
  • TABLE 448 OUROFINO ANIMAL HEALTH: COMPANY OVERVIEW
  • TABLE 449 BIOVAC LTD.: COMPANY OVERVIEW
  • TABLE 450 LABORATOIRE LCV: COMPANY OVERVIEW
  • TABLE 451 KYORITSU SEIYAKU CORPORATION: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 VETERINARY VACCINES MARKET SEGMENTATION & GEOGRAPHICAL SPREAD
  • FIGURE 2 VETERINARY VACCINES MARKET: YEARS CONSIDERED
  • FIGURE 3 VETERINARY VACCINES MARKET: RESEARCH DESIGN
  • FIGURE 4 VETERINARY VACCINES MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 5 VETERINARY VACCINES MARKET: KEY PRIMARY SOURCES
  • FIGURE 6 VETERINARY VACCINES MARKET: KEY DATA FROM PRIMARY SOURCES
  • FIGURE 7 VETERINARY VACCINES MARKET: KEY INDUSTRY INSIGHTS
  • FIGURE 8 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 9 BREAKDOWN OF PRIMARIES (SUPPLY-SIDE PARTICIPANTS): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 10 BREAKDOWN OF PRIMARIES (DEMAND-SIDE PARTICIPANTS): BY END USER, DESIGNATION, AND REGION
  • FIGURE 11 VETERINARY VACCINES MARKET: SUPPLY-SIDE MARKET SIZE ESTIMATION PROCESS
  • FIGURE 12 VETERINARY VACCINES MARKET: REVENUE SHARE ILLUSTRATION FOR ZOETIS (2023)
  • FIGURE 13 VETERINARY VACCINES MARKET: TOTAL REVENUE ANALYSIS (2023)
  • FIGURE 14 VETERINARY VACCINES MARKET: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 15 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
  • FIGURE 16 VETERINARY VACCINES MARKET: TOP-DOWN APPROACH
  • FIGURE 17 VETERINARY VACCINES MARKET: DATA TRIANGULATION
  • FIGURE 18 VETERINARY VACCINES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 19 VETERINARY VACCINES MARKET, BY DISEASE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 20 VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 21 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 22 VETERINARY VACCINES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 23 VETERINARY VACCINES MARKET: REGIONAL SNAPSHOT
  • FIGURE 24 INCREASING COMPANION ANIMAL POPULATION AND RISING INCIDENCE OF ZOONOTIC DISEASES TO DRIVE MARKET
  • FIGURE 25 CHINA AND LIVE ATTENUATED VACCINES COMMANDED LARGEST MARKET SHARE IN 2023
  • FIGURE 26 CHINA TO WITNESS HIGHEST CAGR FROM 2024 TO 2029
  • FIGURE 27 VETERINARY VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 28 PET POPULATION IN MAJOR MARKETS IN 2022 (MILLION)
  • FIGURE 29 VETERINARY VACCINES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
  • FIGURE 30 VETERINARY VACCINES MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 31 VETERINARY VACCINES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 32 VETERINARY VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER
  • FIGURE 34 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 35 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR VETERINARY VACCINE PATENTS (JANUARY 2014–NOVEMBER 2024)
  • FIGURE 36 AVERAGE SELLING PRICE OF LIVESTOCK VACCINES, BY KEY PLAYER, 2023 (USD)
  • FIGURE 37 AVERAGE SELLING PRICE OF PORCINE VACCINES, BY KEY PLAYER, 2023 (USD)
  • FIGURE 38 VETERINARY VACCINES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 39 VETERINARY VACCINES MARKET: NUMBER OF DEALS AND VALUE OF INVESTMENTS, 2018–2022
  • FIGURE 40 ASIA PACIFIC: VETERINARY VACCINES MARKET SNAPSHOT
  • FIGURE 41 CAT POPULATION ACROSS KEY ASIA PACIFIC COUNTRIES (2024)
  • FIGURE 42 EXPECTED GROWTH IN NUMBER OF VETERINARIANS IN NORTH AMERICA
  • FIGURE 43 NORTH AMERICA: VETERINARY VACCINES MARKET SNAPSHOT
  • FIGURE 44 PET (DOG AND CAT) POPULATION IN US AND CANADA (2022)
  • FIGURE 45 PET (DOG AND CAT) POPULATION IN KEY EUROPEAN COUNTRIES (2022)
  • FIGURE 46 PET (DOG AND CAT) POPULATION IN KEY LATIN AMERICAN COUNTRIES (2022)
  • FIGURE 47 CAT POPULATION IN MIDDLE EASTERN & AFRICAN COUNTRIES (2022)
  • FIGURE 48 VETERINARY VACCINES MARKET: REVENUE ANALYSIS OF TOP FIVE PLAYERS (2019–2023)
  • FIGURE 49 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VETERINARY VACCINES MARKET (2023)
  • FIGURE 50 VETERINARY VACCINES MARKET: RANKING OF KEY MARKET PLAYERS (2023)
  • FIGURE 51 VETERINARY VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 52 VETERINARY VACCINES MARKET: COMPANY FOOTPRINT
  • FIGURE 53 VETERINARY VACCINES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 54 VETERINARY VACCINES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 55 VETERINARY VACCINES MARKET: R&D EXPENDITURE OF KEY PLAYERS (2021–2023)
  • FIGURE 56 EV/EBITDA OF KEY VENDORS
  • FIGURE 57 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 58 MERCK & CO., INC.: COMPANY SNAPSHOT
  • FIGURE 59 ZOETIS: COMPANY SNAPSHOT
  • FIGURE 60 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • FIGURE 61 ELANCO: COMPANY SNAPSHOT
  • FIGURE 62 VIRBAC: COMPANY SNAPSHOT
  • FIGURE 63 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT
  • FIGURE 64 HESTER BIOSCIENCES LIMITED: COMPANY SNAPSHOT
  • FIGURE 65 NEOGEN CORPORATION: COMPANY SNAPSHOT
  • FIGURE 66 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: COMPANY SNAPSHOT
  • FIGURE 67 JINYU BIO-TECHNOLOGY CO., LTD.: COMPANY SNAPSHOT

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), American Veterinary Medical Association (AVMA), Animal Health Institute (AHI), National Animal Health Laboratory Network (NAHLN)And Food and Agriculture Organization of the United Nations (FAO)were referred to identify and collect information for the global veterinary vaccines market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the veterinary vaccines market. The primary sources from the demand side include hospitals & clinics, physiotherapy clinics and home care settings. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

Veterinary Vaccines Market

*C-level primaries include CEOs, CFOs, COOs, and VPs.

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

Source: MarketsandMarkets Analysis

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global veterinary vaccines market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players (who contribute at least 70-75% of the market share at the global level). Also, the global veterinary vaccines market was split into various segments and sub-segments based on:

  • List of major players operating in the veterinary vaccines   products market at the regional and/or country level
  • Product mapping of various veterinary vaccines  manufacturers at the regional and/or country level
  • Mapping of annual revenue generated by listed major players from veterinary vaccines (or the nearest reported business unit/product category)
  • Revenue mapping of major players to cover at least 70-75% of the global market share as of 2023
  • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
  • Summation of the market value of all segments/subsegments to arrive at the global point-of-care  diagnostics market

The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

Market Size Estimation (Bottom Up approach & Top down approach)

Veterinary Vaccines Market

Data Triangulation

After arriving at the overall size of the global veterinary vaccines market through the above-mentioned methodology, this market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand- and supply-side participants.

Market Definition

A veterinary vaccine is a biological preparation that provides immunity by stimulating animal’s immune system to recognize and combat specific pathogen. The veterinary vaccines market serves a range of vaccines such as live attenuated, inactivated, recombinant, and toxoid vaccine for a wide range of animals such as poultry, livestock, porcine, aquaculture, and companion animals. Vaccination aids in improving the health of animals, reducing the outbreak of zoonotic diseases, supporting higher productivity, and help securing economic stability.

Stakeholders

  • Animal vaccine manufacturers
  • Animal healthcare product manufacturers
  • Animal vaccine distributors and wholesalers
  • Animal welfare associations
  • Veterinary clinics and care centers
  • Research and consulting firms
  • Veterinary Research and Development Organizations 
  • Contract research organizations
  • Contract manufacturing organizations
  • Venture capitalists

Report Objectives

  • To define, measure, and describe the global veterinary vaccines  market by type, disease, technology, route of administration, end user
  • To provide detailed information about the major factors influencing the market growth (drivers, restraints, challenges, and opportunities)
  • To strategically analyze the regulatory scenario, pricing, value chain analysis, supply chain analysis, ecosystem analysis, technology analysis, Porter’s Five Forces analysis, pipeline analysis and patent analysis
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of market segments in North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To strategically analyze the market structure, profile the key players in the global veterinary vaccines  market, and comprehensively analyze their core competencies
  • To track and analyze company developments such as acquisitions, partnerships, expansions, and product launches and approvals in the veterinary vaccines  market

Previous Versions of this Report

Veterinary Vaccines Market by Type (Porcine, Poultry, Livestock, Companion Animals), Technology (Live Attenuated, Inactivated, Toxoid), Route of Administration (Injection, Intranasal), Distribution Channel (Hospitals, Clinics) - Global Forecast to 2027

Report Code PH 3475
Published in Apr, 2023, By MarketsandMarkets™

Veterinary Vaccines Market by Disease (Swine Pneumonia, Avian Influenza, Rabies, Coccidiosis, Brucellosis, Canine Distemper), Type (Poultry, Livestock, Aquaculture, Porcine, Canine), Technology (Inactivated, Toxoid, Recombinant) - Global Forecast to 2025

Report Code PH 3475
Published in May, 2020, By MarketsandMarkets™

Veterinary/Animal Vaccines Market Type (Porcine, Poultry, Companion Animal, Aquaculture), Disease (Porcine Parvovirus, Swine Pneumonia, Avian Influenza, Rabies, Clostridial Diseases), Technology (Inactivated, Toxoid, Recombinant) - Global Forecast to 2022

Report Code PH 3475
Published in Nov, 2017, By MarketsandMarkets™

Veterinary/Animal Vaccines Market Product (Porcine, (Companion-Canine), (Livestock-Bovine), Poultry, Aquaculture), Diseases (Rabies, FMD, Swine Influenza, Strangles, Furunculous), Technology (DNA, Recombinant, Inactivated, Conjugate) - Forecast to 2021

Report Code PH 3475
Published in Aug, 2016, By MarketsandMarkets™

Veterinary / Animal Vaccines Market by Product (Livestock, Companion, Poultry, Equine, Porcine), Diseases (Rabies, Distemper, Foot & Mouth, Gumboro, Swine& Avian Influenza, Strangles) & Technology (Live attenuated, DNA, Inactivated) - Global Forecast to 2020

Report Code PH 3475
Published in Jun, 2015, By MarketsandMarkets™

Veterinary / Animal Vaccines Market by Product (Livestock, Companion, Poultry, Equine, Porcine), Diseases (Rabies, Distemper, Foot & Mouth, Gumboro, Swine& Avian Influenza, Strangles) & Technology (Live attenuated, DNA, Inactivated) - Global Forecast to 2020

Report Code PH 3475
Published in Jan, 2011, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Veterinary Vaccines Market

DMCA.com Protection Status